Based on our current findings, one can hypothesize that in a subset of cancers, deregulated Hippo signaling due to loss of p190A function is sufficient to bypass CIP in the absence of oncogenic driver mutations in the RTK–RAS–RK pathway. Here, ARHGAP35 is linked to cancer.